The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer 2023 WorldKRAS-G12C mutations occur in approximately 14% of patients with NSCLC.
In the two-year follow-up, pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A, 132 patients with KRAS-G12C-mutated NSCLC were treated with adagrasib 600 mg orally twice daily. The median age of patients was 64 years, with 56.8% being female. At baseline, 19.7% of patients had central nervous system metastases. Patients had received a median of two prior therapies, including platinum-based and checkpoint inhibitor therapies.
According to Shirish Gadgeel, MD from Henry Ford Cancer Institute, Henry Ford Health System, in Detroit, Mich., the results showed a favorable objective response rate of 43.0%, with a median duration of response of 12.4 months. The
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Exhaled breath analysis shows promise in detecting malignant pleural mesotheliomaIdentifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »
Six-year follow-up data on survival, benefits for patients with metastatic NSCLC and nivolumab + ipilimumab treatmentResearch findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.
Source: medical_xpress - 🏆 101. / 51 Read more »
Color of phlegm can predict outcomes for patients with the lung disease, bronchiectasisThe color of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new research presented at the European Respiratory Society International Congress in Milan, Italy.
Source: medical_xpress - 🏆 101. / 51 Read more »
How curiosity sparked pioneering cancer research'I did this research by chance. I was enrolled at the Koch Institute for Integrative Cancer Research at MIT for my postdoctoral work to develop electrical devices with biotechnology. The institute is focused on cancer research and I happened to view other groups' work on cancer cells. I thought, 'This is quite interesting', and wondered if I could extend my work to cancer research,' said Assistant Professor Desmond Loke at the Singapore University of Technology and Design (SUTD).
Source: medical_xpress - 🏆 101. / 51 Read more »
Renfrewshire schoolboy has to 'grow up quick' after mum's cancer diagnosisAlfie Colquhoun, nine, has been making chocolate top hats and crispy cakes in an effort to raise money after his mum, Jennifer, was diagnosed with secondary breast cancer.
Source: Glasgow_Live - 🏆 4. / 97 Read more »